New diabetes drug AMG 127 enters first human safety trials
NCT ID NCT07590193
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug, AMG 127, to see if it is safe for people. It involves 162 healthy adults and people with type 2 diabetes. Researchers will give single or multiple doses and watch for side effects. This is a first step to see if the drug can be developed further for diabetes control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Translational Clinical Research LLC
RECRUITINGAventura, Florida, 33180, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Kidney clues may predict eye swelling after cataract surgery in diabetes patients
- AI-Powered trial asks: does adding a second drug cut heart failure risk?
- Scientists hunt for hidden fat molecules that sabotage insulin
- Can a pharmacist check-in boost medication adherence in diabetes and kidney disease?
- New oral diabetes drug shows promise in early safety trial
- Could a simple breathing exercise ease pain and anxiety during nerve testing?